AIM ImmunoTech (NYSE:AIM – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares […]
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Monte Rosa Therapeutics Announces Leadership Team Promotions tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Wedbush restated their outperform rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) in a report issued on Wednesday morning, Benzinga reports. The firm currently has a $11.00 price objective on the stock. Wedbush also issued estimates for Monte Rosa Therapeutics’ Q2 2024 earnings at ($0.37) EPS, Q3 2024 earnings at ($0.34) EPS, […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Research analysts at Wedbush upped their Q2 2024 earnings per share estimates for Monte Rosa Therapeutics in a note issued to investors on Tuesday, May 21st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.37) per share for the quarter, up […]